secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001628280-23-021758
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus stockholders approve 2023 Retention Equity Award Plan authorizing 600K shares
--------------------------------------------------------------------------------

- Stockholders approved 2023 Retention Equity Award Plan, reserving 600,000 shares of Class A common stock for RSUs.
- Plan aims to retain critical employees; no awards granted yet; Board approved April 17, 2023, stockholders June 7.
- All five Class II director nominees elected with strong shareholder support (82-86% 'for' of votes cast).
- Grant Thornton LLP ratified as independent auditor for FY 2023 with 99.9% 'for' votes.
- Meeting had 88.78% of outstanding shares represented; about 69.5 million shares voted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023021758/0001628280-23-021758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023021758/bvs-20230607.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-021758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer